KD 027

Drug Profile

KD 027

Alternative Names: KD027; SLX 2101; SLx-2101

Latest Information Update: 20 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Surface Logix
  • Developer Kadmon Pharmaceuticals; Surface Logix
  • Class Cardiovascular therapies; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Erectile dysfunction; Hypertension; Raynaud's disease

Most Recent Events

  • 14 Apr 2014 KD 027 is still in phase II trials for Hypertension
  • 14 Apr 2014 Discontinued - Phase-II for Erectile dysfunction in USA (PO)
  • 14 Apr 2014 Discontinued - Phase-II for Raynaud's disease in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top